Kevin Elder, MD
Sports Medicine · Tampa, FLNPI 1598768160
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.9%), education and food and beverage — rather than concentrated in one kind of arrangement. Arthrex accounts for 71.7% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $3,735 and has fallen 87.1% since, to $481 in 2025.
Across 95 payments — averaging $81.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$6K
- MVP Orthopedics Inc$340
- Coastal Medical Technologies LLC$207
- Novo Nordisk$169
- Medtronic$160
- Amgen$150
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$3,00039%
- Food & beverage$2,30930%
- Education$2,40031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 5 | $5,530 |
| MVP Orthopedics Inc | 14 | $340 |
| Coastal Medical Technologies LLC | 3 | $207 |
| Novo Nordisk | 10 | $169 |
| Medtronic | 2 | $160 |
| Amgen | 10 | $150 |
| Penumbra, Inc. | 2 | $149 |
| Bioventus LLC | 2 | $140 |
| AbbVie(2 entities) | 6 | $136 |
| GSK | 5 | $106 |
| Teva Pharmaceuticals USA, Inc. | 6 | $95 |
| Sanofi-aventis U.S. LLC | 3 | $63 |
| Lilly USA, LLC | 3 | $50 |
| Merck | 3 | $50 |
| Amarin Pharma, Inc. | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| IBSA Pharma Inc. | 2 | $42 |
| Theragen, Inc. | 2 | $38 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Pfizer | 2 | $30 |
| Arteriocyte Medical Systems, Inc. | 1 | $22 |
| Gilead | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Fidia Pharma USA Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAZOR X SYSTEM$152
- Indigo System$141
- XCELL$124
- BIOLOGICS CONSUMABLES ACCESSORIES ANGEL PRP$106
How this compares
$7,709 in reported general payments places this provider in the 75th percentile of 402 sports medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 22 | $137 |
| Meloxicam | 50 | $104 |
| Methylprednisolone | 11 | $58 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Tampa
- Seung YiTampa$19K
- Lee KaplanMiami$11.3M
- Patrick SmithNaples$2.9M
- Ryan SimovitchWest Palm Beach$1.1M
- Bruce LevyOrlando$816K
- Gautam YagnikMiami$440K
- Carl DilellaVero Beach$384K
- Adam AnzGulf Breeze$354K
- Stanton LongeneckerJacksonville$330K
- Luga PodestaNaples$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.